Zacks Investment Research
28 Jul 2026, 13:50 UTC · 13w ago
Impact · against what's priced in
Kiniksa Pharmaceuticals shows strong operational momentum with a revenue beat and significant year-over-year growth. While earnings met expectations, the consistent pattern of revenue surprises suggests scaling efficiency.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Kiniksa Pharmaceuticals International (KNSA) reported quarterly revenue of $243.6 million, beating the Zacks Consensus Estimate by 7.09%.
More positive than 64% of claims this week
KNSA's revenue increased from $156.8 million in the prior year to $243.6 million in the current quarter.
Continue reading
5 related stories
Quarterly revenue of $243.6 million beat estimates by 7.09% and represents a substantial increase from $156.8 million a year ago, while earnings met expectations at $0.30 per share.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 50% of claims this week
KNSA reported quarterly earnings of $0.30 per share, meeting the Zacks Consensus Estimate.
More positive than 41% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company reported quarterly earnings and revenue that met or surpassed estimates, and its stock has outperformed the S&P 500.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
39m ago
+42.7%
Price agrees with the score
$90.70 vs $63.54 close before publication (Jul 27) · not market-adjusted
KNSA chart →
